JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

NCT07284134 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

560

Enrollment

OTHER

Sponsor class

Conditions

Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: JS107 for Injection
DRUG: Irinotecan
DRUG: Paclitaxel
DRUG: Docetaxel

Sponsor

Shanghai Junshi Bioscience Co., Ltd.